These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 30585839)

  • 61. A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians.
    Blackstock OJ; Moore BA; Berkenblit GV; Calabrese SK; Cunningham CO; Fiellin DA; Patel VV; Phillips KA; Tetrault JM; Shah M; Edelman EJ
    J Gen Intern Med; 2017 Jan; 32(1):62-70. PubMed ID: 27778215
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preventing HIV Infection in High-Risk Adolescents Using Preexposure Prophylaxis (PrEP).
    Blackwell CW
    J Assoc Nurses AIDS Care; 2018; 29(5):770-774. PubMed ID: 30146018
    [No Abstract]   [Full Text] [Related]  

  • 63. Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties.
    Sanchez Conde M; Vivancos Gallego MJ; Moreno Guillen S
    Farm Hosp; 2017 Sep; 41(5):630-637. PubMed ID: 28847253
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?
    Wong NS; Kwan TH; Tsang OTY; Lee MP; Yam WC; Lam W; Leung WS; Chan JMC; Ho KM; Lee SS
    Sci Rep; 2018 Aug; 8(1):11641. PubMed ID: 30076362
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
    Mugwanya KK; John-Stewart G; Baeten J
    Expert Opin Drug Saf; 2017 Jul; 16(7):867-871. PubMed ID: 28571500
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Pre-Exposure Prophylaxis-Stigma Paradox: Learning from Canada's First Wave of PrEP Users.
    Grace D; Jollimore J; MacPherson P; Strang MJP; Tan DHS
    AIDS Patient Care STDS; 2018 Jan; 32(1):24-30. PubMed ID: 29185801
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interest in HIV pre-exposure prophylaxis in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France).
    Coulaud PJ; Sagaon-Teyssier L; M'madi Mrenda B; Maradan G; Mora M; Bourrelly M; Dembélé Keita B; Keita AA; Anoma C; Babo Yoro SA; Dah TTE; Coulibaly C; Mensah E; Agbomadji S; Bernier A; Couderc C; Laurent C; Spire B;
    Trop Med Int Health; 2018 Oct; 23(10):1084-1091. PubMed ID: 30055043
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Likely impact of pre-exposure prophylaxis on HIV epidemics among men who have sex with men.
    Zablotska IB
    Sex Health; 2017 Feb; 14(1):97-105. PubMed ID: 27883309
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation.
    Ross I; Mejia C; Melendez J; Chan PA; Nunn AC; Powderly W; Goodenberger K; Liu J; Mayer KH; Patel RR
    PLoS One; 2017; 12(3):e0173057. PubMed ID: 28257475
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-acting injectable ART for HIV: a (cautious) step forward.
    Venkatesan P
    Lancet Microbe; 2022 Feb; 3(2):e94. PubMed ID: 35544049
    [No Abstract]   [Full Text] [Related]  

  • 71. One step closer to ultra-long-acting PREP?
    Harper KN
    AIDS; 2019 Mar; 33(3):N2. PubMed ID: 30585839
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.